§
Luxuse
Patent Intelligence
Sign In
Patent US5595722A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5595722A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for identifying an agent which increases TGF-beta levels

Assignee: Poniard Pharmaceuticals Inc
•
Filing: 1995-06-07
•
Granted: 1997-01-21
•
Expires: 2015-06-07
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method for identifying a compound that is a TGF-beta activator or production stimulator is provided.

Inventors

  • 👤 David J. Grainger
  • 👤 James C. Metcalfe

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 06:54
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K31/138; A61K31/33; A61K31/335; A61K31/337; A61K31/38; A61K31/395; A61K31/40; A61K31/4025; A61K31/403; A61K31/4035; A61K31/407; A61K31/70; A61K31/715; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6807; A61K47/6809; A61K47/6811; A61K47/6817; A61K47/6831; A61K47/6835; A61K47/6843; A61K47/69; A61K47/6921; A61K47/6927; A61K47/6929; A61K47/6931; A61K47/6935; A61K47/6937; A61K47/6957; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/71; C07K16/00; C07K16/18; C07K16/22; C07K2317/00; C07K2317/70; C07K2317/73; C07K2317/74; G; G01; G01N; G01N2800/00; G01N2800/32; G01N2800/321; G01N2800/323

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 118 words
A method for identifying an agent which increases the level of TGF-beta in a human comprising: (a) contacting cultured explant human aortic smooth muscle cells (hVSMC) with said agent in an amount effective to reduce or inhibit the rate of proliferation of said cells; (b) contacting said hVSMC resulting from step (a) with a moiety which specifically binds to TGF-beta in an amount effective to block the binding of TGF-beta to the TGF-beta receptors of said hVSMC and determining the rate of proliferation; and (c) determining whether the rate of proliferation of said hVSMC resulting from step (b) is increased relative to the rate of proliferation of the hVSMC which are contacted with said agent in step (a).
Claim 2
Independent Claim 118 words
A method for identifying an agent which increases the level of TGF-beta in a human comprising: (a) contacting cultured explant human aortic smooth muscle cells (hVSMC) with said agent in an amount effective to reduce or inhibit the rate of proliferation of said cells; (b) contacting said hVSMC resulting from step (a) with a moiety which specifically binds to TGF-beta in an amount effective to block the binding of TGF-beta to the TGF-beta receptors of said hVSMC and determining the rate of proliferation; and (c) determining whether the rate of proliferation of said hVSMC resulting from step (b) is increased relative to the rate of proliferation of the hVSMC which are contacted with said agent in step (a).
Claim 3
Dependent Claim 15 words
The method of claim 1 wherein the moiety which binds TGF-beta is a polyclonal antibody.
Claim 4
Dependent Claim 15 words
The method of claim 1 wherein the moiety which binds TGF-beta is a monoclonal antibody.
Claim 5
Dependent Claim 13 words
The method of claim 1 wherein the agent is a TGF-beta production stimulator.
Claim 6
Dependent Claim 12 words
The method of claim 1 wherein the agent is a TGF-beta activator.
Claim 7
Dependent Claim 17 words
The method of claim 1 wherein the agent increases the production of TGF-beta mRNA in said hVSMC.
Claim 8
Dependent Claim 21 words
The method of claim 1 wherein the agent increases the cleavage of the latent form of TGF-beta produced by said hVSMC.

References Cited (Backward Citations)

US3940422A Cited
US4070484A Cited
USRE32944E Cited
US4093709A Cited
US4133814A Cited
US4230862A Cited
US4323707A Cited
US4235988A Cited
US5098903A Cited
US5324736A Cited
US4442119A Cited
US5332584A Cited
US4675189A Cited
US5047431A Cited
US4418068A Cited
US4380635A Cited
US4879315A Cited
US5015666A Cited
US4512762A Cited
US5226430A Cited
US5284763A Cited
US4824436A Cited
US4826672A Cited
US5316766A Cited
US4859585A Cited
US4962091A Cited
US5314679A Cited
US4839155A Cited
EP0260066B1 Cited
US5120535A Cited
US5075321A Cited
US4968350A Cited
US5114719A Cited
US4835002A Cited
US5221620A Cited
US4929602A Cited
US4997652A Cited
US5213580A Cited
US5208019A Cited
US5395842A Cited
US5393785A Cited
US5340925A Cited
US5268358A Cited
US5032679A Cited
US5304541A Cited
US5380716A Cited
US5356713A Cited
US5364632A Cited
US5026537A Cited
US5248764A Cited
US5112305A Cited
US5242397A Cited
US5043335A Cited
US4990538A Cited
US5049132A Cited
US5328471A Cited
US5166143A Cited
US5140012A Cited
US5189046A Cited
US5189212A Cited
US5192525A Cited
US5219548A Cited
US5238714A Cited
US5053033A Cited
US5180366A Cited
US5362424A Cited
US5308622A Cited
US5102402A Cited
US5446070A Cited
US5171217A Cited
US5280016A Cited
US5116864A Cited
US5254594A Cited
US5213576A Cited
US5296492A Cited
US5229495A Cited
US5216126A Cited
US5185260A Cited
US5304325A Cited
US5270047A Cited
US5284869A Cited
US5238950A Cited
US5326757A Cited
US5354562A Cited
US5346993A Cited
US5280109A Cited
US5444164A Cited
US5288711A Cited
US5283257A Cited
US5393763A Cited
US5457117A Cited
US5460807A Cited
US5385935A Cited
US5346702A Cited
GB2273873A Cited
US5354774A Cited
US5308862A Cited
US5453436A Cited
US5472985A Cited
US5445941A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2000-01-21 2000-07-22 2001-01-21 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2004-01-21 2004-07-22 2005-01-21 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2008-01-21 2008-07-22 2009-01-21 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag